Elite Pharmaceuticals, Inc.
165 Ludlow Avenue
Northvale
New Jersey
07647
United States
Tel: 201-750-2646
Fax: 201-750-2755
Website: http://www.elitepharma.com/
Email: eliteinfo@elitepharma.com
238 articles about Elite Pharmaceuticals, Inc.
-
Elite Pharmaceuticals, Inc. Reports Financial Results for Third Quarter of Fiscal Year 2024 ended December 31, 2023 and Provides Conference Call Information
2/14/2024
Elite Pharmaceuticals, Inc. announced results for the third quarter of fiscal year 2024 ended December 31, 2023.
-
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Third Quarter 2024 Financial Results on February 15, 2024
2/8/2024
Elite Pharmaceuticals, Inc. announced today that the third quarter financial results of the 2024 fiscal year will be released on Wednesday, February 14, 2024.
-
Elite Pharmaceuticals Files ANDA with US FDA to Market Central Nervous System Stimulant
12/26/2023
Elite Pharmaceuticals, Inc. announced the US Food and Drug Administration's acceptance for review of an Abbreviated New Drug Application on December 21, 2023, for an undisclosed generic drug product in a class of medications known as central nervous stimulants.
-
Elite Pharmaceuticals Announces First Product Shipment of Generic Adderall XR(R) to Marketing Partner Prasco, LLC
12/12/2023
Elite Pharmaceuticals, Inc. today announced the first shipment of generic Adderall XR to its distribution and marketing partner Prasco, LLC.
-
Elite Pharmaceuticals, Inc. Reports Financial Results for Second Quarter of Fiscal Year 2024 ended September 30, 2023 and Provides Conference Call Information
11/14/2023
Elite Pharmaceuticals, Inc., a specialty pharmaceutical company engaged in the development, manufacture, and distribution of niche generic products, announced results for the second quarter of fiscal year 2024 ended September 30, 2023.
-
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2024 Financial Results on November 15, 2023
11/10/2023
Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP), a specialty pharmaceutical company developing niche generic products, announced today that the second quarter financial results of the 2024 fiscal year will be released on Tuesday, November 14, 2023.
-
Elite Pharmaceuticals Files ANDA with US FDA to Market Opiate Analgesic Product
9/25/2023
Elite Pharmaceuticals, Inc. announced that it filed an Abbreviated New Drug Application on August 17, 2023, and was accepted for review by the US Food and Drug Administration on September 19, 2023 for an undisclosed generic drug product in a class of medications called opiate analgesics.
-
Elite Pharmaceuticals, Inc. Appoints Carter Ward as Chief Financial Officer
9/7/2023
Elite Pharmaceuticals, Inc., a specialty pharmaceutical company developing and manufacturing niche generic products, announced the appointment of Carter Ward as its Chief Financial Officer, effective September 5, 2023.
-
Elite Pharmaceuticals, Inc. Reports Financial Results for First Quarter of Fiscal Year 2024 ended June 30, 2023 and Provides Conference Call Information
8/14/2023
Elite Pharmaceuticals, Inc., a specialty pharmaceutical company engaged in the development, manufacture, and distribution of niche generic products, announced results for the first quarter of fiscal year 2024 ended June 30, 2023.
-
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss First Quarter 2024 Financial Results on August 15, 2023
8/9/2023
Elite Pharmaceuticals, Inc. announced today that the first quarter financial results of the 2024 fiscal year will be released on Monday, August 14, 2023.
-
Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2023 and Provides Conference Call Information
6/29/2023
Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharmaceutical company developing niche generic products, announced results for the fiscal year ended March 31, 2023 ("Fiscal 2023").
-
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Fiscal Year 2023 Financial Results on June 30, 2023
6/22/2023
Elite Pharmaceuticals, Inc., a specialty pharmaceutical company developing niche generic products, announced that it would release its 2023 year-end financial results on Thursday, June 29, 2023.
-
Elite Pharmaceuticals, Inc. Appoints Mark Pellegrino as Chief Financial Officer
5/3/2023
Elite Pharmaceuticals, Inc., a specialty pharmaceutical company developing and manufacturing niche generic products, announced the appointment of Mark Pellegrino as its Chief Financial Officer, effective May 1, 2023.
-
Elite Pharmaceuticals Files ANDA with US FDA to Market Antimetabolite Product
4/20/2023
Elite Pharmaceuticals, Inc. announced that it filed an Abbreviated New Drug Application with the US Food and Drug Administration for an undisclosed generic drug product in a class of medications called antimetabolites.
-
Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2023 ended December 31, 2022 and Provides Conference Call Information
2/14/2023
Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharmaceutical company developing niche generic products, announced results for the third quarter of fiscal year 2023 ended December 31, 2022 ("Third Quarter").
-
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Third Quarter 2023 Financial Results on February 15, 2023
2/8/2023
Elite Pharmaceuticals, Inc. announced today that the third quarter financial results of the 2023 fiscal year will be released on Tuesday, February 14, 2023.
-
Elite Pharmaceuticals Reports Positive Results from a Pivotal Bioequivalence Study - February 7, 2023
2/7/2023
Elite Pharmaceuticals, Inc. today reported positive results from pivotal fasted bioequivalence studies for an undisclosed generic drug product in a class of medications called antimetabolites.
-
Elite Pharmaceuticals Files ANDA with US FDA to Market Dopamine Agonist
12/22/2022
Elite Pharmaceuticals, Inc. today announced that it filed an Abbreviated New Drug Application (ANDA) with the US Food and Drug Administration (FDA) for an undisclosed extended-release generic drug product in a class of medications called dopamine agonists.
-
Elite Pharmaceuticals Reports Positive Results from a Pivotal Bioequivalence Study
11/2/2022
Elite Pharmaceuticals, Inc. today reported positive results from pivotal fed and fasted bioequivalence studies for an undisclosed extended-release generic drug product in a class of medications called dopamine agonists.
-
Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2023 ended June 30, 2022, and Provides Conference Call Information
8/15/2022
Elite Pharmaceuticals, Inc., a specialty pharmaceutical company developing niche generic products, announced results for the first quarter of fiscal year 2023 ended June 30, 2022.